Real-world experience of ocrelizumab in multiple sclerosis patients in Latin America

Juan Ignacio ROJAS; Liliana PATRUCCO; Manuel FRUNS; Giesela HORNUNG; José FLORES; Edgar CARNERO CONTENTTI; Pablo Adrian LOPEZ; Juan Pablo PETTINICCHI; Alejandro CARIDE; Lorna GALLEGUILLOS; Jorge BARAHONA; DIAZ TAPIA, VIOLETA DEL CARMEN; Marianella HERNÁNDEZ; Ricardo ALONSO; Edgardo CRISTIANO

doi:10.1590/0004-282X-ANP-2020-0339

Real-world experience of ocrelizumab in multiple sclerosis patients in Latin America

Journal

Arquivos de Neuro-Psiquiatria

ISSN

1678-4227

0004-282X

Date Issued

2021

Author(s)

Juan Ignacio ROJAS

Liliana PATRUCCO

Manuel FRUNS

Giesela HORNUNG

José FLORES

Edgar CARNERO CONTENTTI

Pablo Adrian LOPEZ

Juan Pablo PETTINICCHI

Alejandro CARIDE

Lorna GALLEGUILLOS

Jorge BARAHONA

DIAZ TAPIA, VIOLETA DEL CARMEN

Facultad de Medicina Clínica Alemana Universidad del Desarrollo

Marianella HERNÁNDEZ

Ricardo ALONSO

Edgardo CRISTIANO

Type

Resource Types::text::journal::journal article

DOI

10.1590/0004-282X-ANP-2020-0339

URL

https://investigadores.udd.cl/handle/123456789/7500

Abstract

ABSTRACT Background: Despite the abundance of information concerning ocrelizumab in phase III clinical trials, there is scarce evidence regarding real-world patient profiles. Objective: The aim of this study was to investigate patient profiles, effectiveness and persistence with treatment among patients who used ocrelizumab for treatment of multiple sclerosis in Latin America. Methods: This was a retrospective multicenter study in Argentina, Chile and Mexico. Medical record databases on patients who received ocrelizumab were analyzed. Demographic and clinical variables were described, along with effectiveness outcomes, which included the proportions of patients free from clinical relapses, from disability progression and from new or enlarging T2 or T1 gadolinium-enhancing lesions, on annual magnetic resonance imaging. Results: A total of 81 patients were included. The most frequent phenotype was relapsing-remitting MS, in 64.2% of the patients. The mean age at study entry was 41.3 ± 12.0 years and 51.8% were women. A total of 38% had had relapse activity during the 12 months before starting on ocrelizumab, with a mean relapse rate of 1.3 ± 0.6 during that period. 75% were free from clinical relapses and 91% were free from gadolinium-enhancing lesions in the relapsing-remitting course. Ocrelizumab discontinuation during the first 12 months was observed in three patients (3.7%). The mean persistence observed during the first-year follow-up was 338 ± 24 days. Conclusions: Our study is in line with previous randomized clinical trials and recent real-world studies describing patient profiles, effectiveness and persistence regarding ocrelizumab treatment in multiple sclerosis patients in Latin America.